Efficacy and Safety of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) in Severe Sepsis
JAMA2003Vol. 290(2), pp. 238–238
Citations Over TimeTop 1% of 2003 papers
Edward Abraham, Konrad Reinhart, Steven M. Opal, Ignace Demeyer, Christopher J. Doig, Angel López Rodríguez, Richard Beale, Petr Svoboda, Pierre François Laterre, Stuart H. Simon, Bruce Light, Herbert Spapen, Judy Stone, Allan Seibert, C. Peckelsen, C. De Deyne, Russell G. Postier, Ville Pettilä, Charles L. Sprung, Antonio Artigas, Sandra Percell, Vincent Shu, Christian Zwingelstein, Jeffrey Tobias, Lona Poole, James C. Stolzenbach, Abla A. Creasey
Abstract
Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR. Tifacogin administration was associated with an increase in risk of bleeding, irrespective of baseline INR.
Related Papers
- → Evolving role of tissue factor and its pathway inhibitor(2002)49 cited
- → Presence of Tissue Factor Pathway Inhibitor in Human Atherosclerotic Plaques Is Associated With Reduced Tissue Factor Activity(1998)88 cited
- Tissue Factor and Tissue Factor Pathway Inhibitor in Coronary Atherosclerotic Plaque(2007)
- Tissue Factor and Tissue Factor Pathway Inhibitor in Coronary Heart Disease(2008)
- 18) Tissue factor (TF) /Tissue factor pathway Inhibitor (TFPI) Ratioによる安定狭心症患者のPTCA後再狭窄の予測について(1999)